Text Analysis of China's Pediatric Medication Policies Based on the Framework of

Meixiang GAO; Hong ZHU; Hongwei CHEN; Minxiang CAI; Ya LI; Jiaan YANG; Yiru YIN; Haohao FENG

Return

Text Analysis of China's Pediatric Medication Policies Based on the Framework of"Policy Instrument-Stakeholder"

VernacularTitle:基于"政策工具-利益相关者"框架的我国儿童药物政策文本分析
Author: Meixiang GAO ¹ ; Hong ZHU ; Hongwei CHEN ; Minxiang CAI ; Ya LI ; Jiaan YANG ; Yiru YIN ; Haohao FENG
Author Information

1. 哈尔滨医科大学人文社会科学学院,哈尔滨 150086
Publication Type:Journal Article
Keywords: Pediatric drugs; Policy tools; Policy analysis; Content analysis method; Stakeholder
From: Herald of Medicine 2025;44(7):1179-1184
CountryChina
Language:Chinese
Abstract: Objective To analyze the policy texts related to pediatric medications in China over the past decade,to explore the deficiencies in existing policy formulation from the perspective of stakeholders,and to propose reasonable optimization suggestions based on the current situation.Methods Collecting national-level policies related to pediatric drugs in China from 2013 to 2023,a two-dimensional policy analysis framework of"Policy tools-Stakeholder"were established.And the content analysis method was used to code,categorize,and statistically analyze the policy texts.Results A total of 54 pediatric drug policies were included in the analysis.In terms of policy tools,a total of 197 policy codes were formed,with environmental tools being the most prevalent with 92 codes(46.70％),primarily consisting of regulatory management tools(28 codes,30.43％).This was followed by supply-oriented tools with 53 codes(26.90％),mainly focused on the issuance of technical guidelines(21 codes,39.62％).Demand-oriented tools accounted for the least with 52 codes(26.40％),with inter-departmental collaboration tools having the highest proportion(17 codes,32.69％).In the dimension of stakeholders,a total of 223 policy codes were formed,with the government having the highest number of codes at 133(59.64％),followed by medical institutions with 56 codes(25.11％).The proportions for medical personnel,pharmaceutical companies,and patients were similar,with 14 codes(6.28％),11 codes(4.93％),and 9 codes(4.04％),respectively.Conclusions Pediatric drugs face challenges with policy tools where supply-oriented tools,particularly those providing financial support,suffer from insufficient policy depth and customization.The demand-oriented tools have a low proportion,leading to structural imbalance and underutilized effectiveness;the environment-oriented tools focus more on regulation than incentives,restricting the accessibility of pediatric drugs;the potential of multiple stakeholders is not fully activated,and there is a lack of policies centered around pediatric patients.To address these issues,supply-oriented policy tools need to establish a diversified financial support model and clearly define the scope of coverage.Demand-oriented policy tools require further adjustments to the catalog,procurement upgrades,and international collaborative research to reshape the pediatric drug security system.Environmental policy tools should enhance economic support,strengthen intellectual property rights,and implement targeted education to build a development ecosystem for pediatric drugs.Regarding stakeholders,it is essential to strengthen multi-stakeholder collaboration and optimize pediatric drug policy tools with a patient-centered approach.